645 related articles for article (PubMed ID: 19224844)
1. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.
Tuttle TM; Jarosek S; Habermann EB; Arrington A; Abraham A; Morris TJ; Virnig BA
J Clin Oncol; 2009 Mar; 27(9):1362-7. PubMed ID: 19224844
[TBL] [Abstract][Full Text] [Related]
2. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.
Arrington AK; Jarosek SL; Virnig BA; Habermann EB; Tuttle TM
Ann Surg Oncol; 2009 Oct; 16(10):2697-704. PubMed ID: 19653045
[TBL] [Abstract][Full Text] [Related]
3. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.
Tuttle TM; Habermann EB; Grund EH; Morris TJ; Virnig BA
J Clin Oncol; 2007 Nov; 25(33):5203-9. PubMed ID: 17954711
[TBL] [Abstract][Full Text] [Related]
4. Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience.
Soran A; Falk J; Bonaventura M; Keenan D; Ahrendt G; Johnson R
Ann Surg Oncol; 2007 Feb; 14(2):646-51. PubMed ID: 17122987
[TBL] [Abstract][Full Text] [Related]
5. Incidence of and treatment for ductal carcinoma in situ of the breast.
Ernster VL; Barclay J; Kerlikowske K; Grady D; Henderson C
JAMA; 1996 Mar; 275(12):913-8. PubMed ID: 8598618
[TBL] [Abstract][Full Text] [Related]
6. Impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy.
Ashfaq A; McGhan LJ; Pockaj BA; Gray RJ; Bagaria SP; McLaughlin SA; Casey WJ; Rebecca AM; Kreymerman P; Wasif N
Ann Surg Oncol; 2014 Sep; 21(9):2934-40. PubMed ID: 24756811
[TBL] [Abstract][Full Text] [Related]
7. Are mastectomy rates really increasing in the United States?
Habermann EB; Abbott A; Parsons HM; Virnig BA; Al-Refaie WB; Tuttle TM
J Clin Oncol; 2010 Jul; 28(21):3437-41. PubMed ID: 20548000
[TBL] [Abstract][Full Text] [Related]
8. The influence of age on the breast surgery decision-making process.
Bleicher RJ; Abrahamse P; Hawley ST; Katz SJ; Morrow M
Ann Surg Oncol; 2008 Mar; 15(3):854-62. PubMed ID: 18058182
[TBL] [Abstract][Full Text] [Related]
9. Perceptions of contralateral breast cancer: an overestimation of risk.
Abbott A; Rueth N; Pappas-Varco S; Kuntz K; Kerr E; Tuttle T
Ann Surg Oncol; 2011 Oct; 18(11):3129-36. PubMed ID: 21947590
[TBL] [Abstract][Full Text] [Related]
10. Results of 23,810 cases of ductal carcinoma-in-situ.
Sumner WE; Koniaris LG; Snell SE; Spector S; Powell J; Avisar E; Moffat F; Livingstone AS; Franceschi D
Ann Surg Oncol; 2007 May; 14(5):1638-43. PubMed ID: 17245612
[TBL] [Abstract][Full Text] [Related]
11. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base.
Pesce CE; Liederbach E; Czechura T; Winchester DJ; Yao K
J Am Coll Surg; 2014 Jul; 219(1):19-28. PubMed ID: 24862886
[TBL] [Abstract][Full Text] [Related]
12. Contralateral prophylactic mastectomy. Predictors of significant histologic findings.
Goldflam K; Hunt KK; Gershenwald JE; Singletary SE; Mirza N; Kuerer HM; Babiera GV; Ames FC; Ross MI; Feig BW; Sahin AA; Arun B; Meric-Bernstam F
Cancer; 2004 Nov; 101(9):1977-86. PubMed ID: 15389473
[TBL] [Abstract][Full Text] [Related]
13. Regional differences in the incidence and treatment of carcinoma in situ of the breast.
Choi WS; Parker BA; Pierce JP; Greenberg ER
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):317-20. PubMed ID: 8722225
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: Analysis of Surveillance, Epidemiology, and End Results data.
You Q; Chen K; Li Y; Lai J; Fang Y; Shen S; Liu Y; Su F; Yu F
Breast; 2018 Aug; 40():147-155. PubMed ID: 29804045
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival.
Joslyn SA
Breast J; 2006; 12(1):20-7. PubMed ID: 16409583
[TBL] [Abstract][Full Text] [Related]
16. Predictors of surgical margin status in breast-conserving surgery within a breast screening program.
Kurniawan ED; Wong MH; Windle I; Rose A; Mou A; Buchanan M; Collins JP; Miller JA; Gruen RL; Mann GB
Ann Surg Oncol; 2008 Sep; 15(9):2542-9. PubMed ID: 18618180
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
[TBL] [Abstract][Full Text] [Related]
18. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
19. Variations in treatment of ductal carcinoma in situ of the breast: a population-based study in the East Netherlands.
Schouten van der Velden AP; Van Dijck JA; Wobbes T
Eur J Surg Oncol; 2007 May; 33(4):424-9. PubMed ID: 17084060
[TBL] [Abstract][Full Text] [Related]
20. Should the use of contralateral prophylactic mastectomy be increasing as it is?
Wood WC
Breast; 2009 Oct; 18 Suppl 3():S93-5. PubMed ID: 19914552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
